<DOC>
	<DOCNO>NCT02979977</DOCNO>
	<brief_summary>This single arm Phase II study patient recurrent metastatic squamous cell carcinoma head neck , previously treat platinum base regimen immune checkpoint inhibitor . The primary objective evaluate efficacy combination cetuximab afatinib .</brief_summary>
	<brief_title>Dual Inhibition EGFR With Afatinib Cetuximab Treatment Recurrent Metastatic Squamous Cell Cancers Head Neck</brief_title>
	<detailed_description>Patients recurrent/metastatic squamous cell carcinoma head neck , previously treat platinum base regimen immune checkpoint inhibitor eligible participation study . After baseline evaluation biopsy , treat weekly IV cetuximab daily oral afatinib . Biopsy repeat feasible 4 week therapy disease progression end treatment . Treatment continue disease progression development grade 3 high drug relate toxicity fail resolve Grade 1 despite appropriate supportive care .</detailed_description>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirm squamous cell carcinoma head neck metastatic recurrent treatable curative intent . Previous progression intolerance one line therapy either platinum immunotherapy ( pembrolizumab nivolumab ) . Prior chemotherapy induction , organ preservation adjuvant setting permit complete 4 month prior enrollment current study . Prior cetuximab permit give 9 dos combination radiation therapy chemoradiation therapy initial treatment locally advanced disease complete least 4 month prior study enrollment . Measurable disease base RECIST v 1.1 . ECOG performance status ≤2 Adequate organ function , define following : Hemoglobin ≥ 9 g/dl . Absolute neutrophil count ( ANC ) ≥1500 / mm3 . ( ANC &gt; 1000/mm3 may consider special circumstance benign cyclical neutropenia judge investigator discussion sponsor ) . Platelet count ≥75,000 / mm3 . Estimated creatinine clearance &gt; 45ml / min . Total Bilirubin ≤ 1.5 time upper limit ( institutional/central ) normal ( Patients Gilbert 's syndrome total bilirubin must ≤4 time institutional upper limit normal ) . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) ≤ three time upper limit ( institutional/central ) normal ( ULN ) ( relate liver metastasis ≤ five time ULN ) . Recovered previous therapy relate toxicity ≤Grade 1 baseline study entry ( except stable sensory neuropathy ≤Grade 2 alopecia ) . Ability understand willingness sign write informed consent consistent ICHGCP guideline . Negative urine serum pregnancy test woman childbearing potential Prior erlotinib , gefitinib lapatinib therapy prior exposure investigational EGFR panErbB reversible irreversible inhibitor prior panitumumab investigational EGFRdirected monoclonal antibody . Hormonal treatment within 2 week prior start study treatment ( continue use antiandrogens and/or gonadorelin analogue treatment prostate cancer permit ) Radiotherapy within 4 week prior enrollment . Palliative radiation target organ may allow 2 week prior enrollment , long target lesion monitor response study treatment . Major surgery within 4 week start study treatment schedule surgery project course study . Known hypersensitivity afatinib excipients History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure NYHA classification ≥ 3 , unstable angina poorly control arrhythmia determine investigator . Myocardial infarction within 6 month . Women childbearing potential ( WOCBP ) men able father child , unwilling abstinent use highly effective method birth control result low failure rate le 1 % per year use consistently correctly prior study entry , duration study participation least 4 week treatment end . Women pregnant , nursing , plan become pregnant trial . Any history concomitant condition , opinion Investigator , would compromise patient 's ability comply study interfere evaluation efficacy safety test drug . Previous concomitant malignancy site , except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 3 year consider cure . Requiring treatment prohibit concomitant medication stop duration trial participation . Known preexist interstitial lung disease . Any history presence poorly control gastrointestinal disorder could affect absorption study drug ( e.g . Crohn 's disease , ulcerative colitis , chronic diarrhea , malabsorption ) . Active hepatitis B infection ( define presence HepB sAg and/ Hep B DNA ) , active hepatitis C infection ( define presence Hep C RNA ) and/or know HIV carrier . Patients brain subdural metastasis eligible , unless complete local therapy discontinue use corticosteroid , anticonvulsant stable dose corticosteroid least 4 week start study treatment . Any symptom attribute brain metastasis must stable least 4 week start study treatment . Leptomeningeal carcinomatosis , diagnose cytology appropriate imaging .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>